Radiopharm Theranostics
RADX | NASDAQ
$0.72
-$0.04 (-5.26%)
At close: Nov 16, 2026, 3:59 PM ET
$0.70
-$0.02 (-2.78%)
After-hours:
Nov 16, 2026, 7:58 PM ET
-5.26%
(1D)No price chart data available for 1D timeframe.
Rating
44.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #416/1021 (Top 41%)
Key Statistics
Market Data
Market Cap $930.08K
1D Range
0.72 0.81
52W Range
0.72 10.63
Valuation (TTM)
PE 0
PB 0.05
EV/EBITDA 0.04
Valuation (NTM)
Forward PE N/A
Forward PEG 0.02
Price Target $6.00
Cash Flow
FCF Yield -1610.7%
SBC Adj. FCF Yield -1610.7%
SBC Impact N/A
Margins
Gross Margin -39.4%
Operating Margin -2550.7%
FCF Margin -805.8%
Growth (CAGR)
Revenue 3Y | 5Y 110.0% |
N/A
Dil EPS 3Y | 5Y 102.9% |
N/A
FCF 3Y | 5Y 57.8% |
N/A
Returns
ROA -91.7%
ROE -144.2%
ROIC -158.1%
Financial Health
Net Cash
A$4.14M ($2.86M)
Current Ratio 1.16
Interest Coverage -626.93
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to a...
Sector Healthcare
Industry Biotechnology
Employees 14
IPO Date Dec 5, 2024
Website www.radiopharmtheranostics.com
Fiscal Year July - June
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$6.00
Upside
+733.33%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove RADX